Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.

Abstract: The invention relates to quinoxaline derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

Abstract: ?-amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer.

Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.

Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

Abstract: The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices as well as to ophthalmic devices comprising such compounds.

Abstract: The present invention relates to Tetracyclic Heterocycle Compounds of Formula and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, R1, R2, R3 and R7 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

Abstract: The present invention relates to a directly compressible composition for the production of tablets which comprise fine-grained polyvinyl alcohols (PVAs) and fine-grained microcrystalline celluloses (MCCs) in a co-mixture. The present invention also relates to the use of this mixture and to a process for the preparation thereof.

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

Abstract: Liquid-crystalline media comprising one or more compounds of formula T as defined in claim 1, and high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.

Abstract: The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.

Abstract: The present invention relates to laser-markable polymers and coatings which are distinguished by the fact that they comprise tin/antimony oxide-coated spherical TiO2 particles of defined particle size as laser additive.

Abstract: The present invention relates to interference pigments based on transparent, low-refractive-index, flake-form substrates which have a high-refractive-index coating consisting of TiO2 having a layer thickness of 20-200 nm and optionally an outer protective layer, and to the use thereof in paints, coatings, printing inks, security printing inks, plastics, button pastes, ceramic materials, glasses, for seed coloring, as dopants in the laser marking of plastics and papers, as additive for the laser welding of plastics, as additive for coloring in the foods and pharmaceuticals sectors, and in cosmetic formulations and for the preparation of pigment compositions and dry preparations.

Abstract: The present invention relates to a process for the production of virtual three-dimensional patterns in mouldings, in particular to an injection-moulding process for the production of mouldings having a virtual three-dimensional pattern which is formed by flake-form effect pigments, to the mouldings produced by means of this process, and to the use thereof, in particular for decorative purposes.

Abstract: The invention relates to a method for printing a surface (2) with a fluid which contains an organic semiconductor material. The fluid is transported from a storage container (7) through a supply line (5) to a printing head (3), which can be moved over the surface (2), and printed onto the surface (2) by the printing head (3). At least one part of the fluid which is transported through the supply line (5) to the printing head (3) is returned to the storage container (7) via a return line (6), wherein a fluid circuit is formed, and the fluid in the fluid circuit flows through a cleaning device (12) with which the fluid is cleaned. The fluid returned to the storage container (7) flows around and surrounds the fluid being transported in the supply line (5) to the printing head (3) at least in some regions.

Abstract: A method for electrically driving a switchable optical element is provided wherein the state of a liquid-crystalline medium is controlled by an applied electric field. The provided method comprises at least one of a) switching from a scattering state to a clear state, b) switching from a clear state to a scattering state, c) holding a scattering state.

Abstract: The invention pertains to a kit for assembling a disposable applicator for inserting an implant, in particular a rod-like implant containing an active substance, under the skin of a human or animal, the kit comprising a first component, in turn comprising a main housing part providing a handle for grasping and maneuvering the applicator, a cannula, and a cannula holder mounted in the main housing part, the main housing part having an opening which allows introduction of an implant into the proximal end of the cannula or the cannula holder, and, a second component for closing said opening, in turn comprising a second housing part and a rod attached to or forming an integral whole with the second housing part and mountable inside the cannula or the cannula holder.

Abstract: The present invention is directed to compounds of generic formula (I): or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist. The invention is further directed to methods of treating a patient (preferably a human) for diseases or disorders in which the A2A-receptor is involved. The invention further involves use of the compounds as an A2A-receptor antagonist and/or inhibitor for the preparation of a medicament for the treatment and/or prevention of diseases associated with inhibiting the receptor, which includes central nervous system disorders such as Parkinson's disease. The invention is also directed to pharmaceutical compositions which include an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.

Abstract: The invention relates to a liquid-crystalline medium, in particular based on a mixture of polar compounds, and to the use thereof for an active-matrix display, in particular based on the VA, SA-VA, IPS, PS-IPS, FFS, PS-FFS, UB-FFS or PS-UB-FFS effect.